Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register Vertex for InfoPages here.
Vertex - Latest News [Page 1]
Vertex Statement On Confirmation Of Trikafta Funding
Tuesday, 7 March 2023, 12:08 pm | Vertex
Vertex welcomes the announcement by Pharmac confirming the listing of Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) on the Pharmaceutical Schedule from 1 April 2023 for eligible New Zealanders with cystic fibrosis ages 6 years and older ... More >>
Vertex Announces Provisional Agreement With Pharmac For The Reimbursement Of TRIKAFTA®
Sunday, 4 December 2022, 7:08 pm | Vertex
Vertex Announces Provisional Agreement with Pharmac for the reimbursement of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 6 Years and Older With at Least One F508del Mutation in the CFTR Gene - Under ... More >>
Vertex Statement Regarding Trikafta
Friday, 16 September 2022, 11:04 am | Vertex
Vertex is extremely disappointed that Pharmac has decided not to prioritise funding of Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for New Zealand’s cystic fibrosis (CF) patients. We understand that Pharmac must make choices within ... More >>
Vertex Pharmaceutical RE PTAC Minutes
Wednesday, 23 February 2022, 1:34 pm | Vertex
Vertex is disappointed that after Pharmac’s Respiratory Sub-Committee described Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) as a “paradigm shifting” treatment and recommended it as a high priority for funding, the Pharmacology and ... More >>
Medsafe Consents Trikafta
Thursday, 9 December 2021, 1:07 pm | Vertex
Vertex today announced it has gained consent from Medsafe for the use of Trikafta® (elexacaftor/tezacaftor/ ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in patients in New Zealand, ages six and over who have at least one F508del ... More >>
